Wednesday, February 25, 2015

EyewireTV — FDA Advisory Committee Recommends Approval of Avedro's Cross-Linking Platform

In this week’s EyewireTV, a joint FDA advisory panel recommends approval of Avedro’s combined riboflavin ophthalmic solutions and ultraviolet light irradiation for corneal collagen cross-linking; and Valeant agrees to acquire Salix Pharmaceuticals, a maker of gastrointestinal drugs, in anall cash deal valued at about $10.1 billion. Also, a large study shows that laser cataract surgery and standard phacoemulsification are equally safe procedures. (1314 Views)

Watch Video

Thursday, February 19, 2015

EyewireTV — Protocol T Study Results, Avedro Cross-Linking FDA Hearing

Results of the government-sponsored Protocol T study show that three agents used to treat diabetic macular edema were effective and safe, however, the relative effect correlated with patients’ baseline visual acuities; and a date is set for an FDA advisory panel to review Avedro’s new drug application for its corneal cross-linking platform. (1969 Views)

Watch Video

Wednesday, February 11, 2015

EyewireTV — Lucentis DR Approval, Caribbean Eye Highlights

In this week's EyewireTV, the FDA expands the approved use of Lucentis (ranibizumab) to treat diabetic retinopathy in patients with diabetic macular edema; and results of an international study show that the InnFocus MicroShunt implant lowered IOP and reduced reliance on glaucoma medication. Also, the annual Caribbean Eye meeting takes place in San Juan, Puerto Rico. Co-chair Dee Stephenson, MD, talks about the highlights of the meeting and what’s in store for next year. (1381 Views)

Watch Video

Wednesday, February 04, 2015

EyewireTV — New Glaucoma System, Pazeo FDA Approval, Tecnis Multifocal IOLs

In this week’s EyewireTV, Iridex is granted FDA 510(k) clearance for the Cyclo G6 Laser System for the treatment of multiple stages of glaucoma; and Alcon receives FDA approval for Pazeo (olopatadine hydrochloride ophthalmic solution) 0.7% for the treatment of ocular itching associated with allergic conjunctivitis. Also, Abbott Medical Optics announces that two new Tecnis multifocal IOLs (+2.75 D and +3.25 D) have received FDA approval. (2007 Views)

Watch Video

Wednesday, January 28, 2015

EyewireTV — Ophthalmic Pioneer George Waring III Passes Away at Age 73

In this week’s EyewireTV, ophthalmic pioneer George Waring III, MD, FACS, FRCOphth, who was influential in getting excimer laser vision correction surgery approved in the United States, passes away at the age of 73; and Abbott Medical Optics announces FDA clearance for the creation of intracorneal pockets with the iFS Advanced Femtosecond Laser System. Also, Regeneron announces that Eylea has been recommended for approval in Europe for the treatment of visual impairment due to macular edema secondary to central or branch retinal vein occlusion. (2466 Views)

Watch Video

Wednesday, January 21, 2015

EyewireTV — Victus Upgrades, Eidon US Launch

In this week's EyewireTV, Bausch + Lomb receives FDA 510(k) clearance for an advanced swept-source OCT imaging system and updated software for its Victus Femtosecond Laser Platform, and at the Royal Hawaiian Eye Meeting in Maui, CenterVue announces the US launch of the Eidon imaging system. Also, InnFocus provides updates on its MicroShunt glaucoma drainage implant. (2510 Views)

Watch Video

Wednesday, January 14, 2015

EyewireTV — New Postoperative Drop Formulation, 5-Year Cataract Surgery Study

In this week's EyewireTV, Imprimis Pharmaceuticals plans to introduce LessDrops, a proprietary eye drop formulation to be administered following laser refractive and cataract surgery; and a large, 5-year study examining trends in cataract surgery shows decreasing visual thresholds for surgery, decreasing surgical complication rates, and increasing visual outcomes. Also, Synergetics USA acquires Sterimedix, a provider of single-use ophthalmic instruments, in a deal worth up to $13.5 million. (2908 Views)

Watch Video

Wednesday, January 07, 2015

EyewireTV — 2014 FDA Drug Approvals, Digital Eye Strain

In this week's EyewireTV, the FDA’s drug approval rate hit an 18-year high in 2014 as the agency gave the green light to 44 new medicines; and new research shows that nearly 95% of Americans spend 2 or more hours every day on digital devices, highlighting the need to address the rising occurrence of eye strain. Also, Nidek announces the launch of the Retina Scan Duo, a device that combines high-definition OCT and fundus camera capabilities. (1914 Views)

Watch Video

Wednesday, December 31, 2014

EyewireTV — 2014 Year in Review

In this week's EyewireTV, a look back at some of EyewireTV’s most significant stories from 2014. It was an active year in ophthalmology, marked by mergers and acquisitions, landmark studies, new indications for well-known retina agents, and technology advancements across all areas of eye care. The year also included an aggressive and high-profile hostile takeover attempt. (2098 Views)

Watch Video

Tuesday, December 23, 2014

EyewireTV — Ophthalmic Leaders Provide Pipeline Updates

In this week's EyewireTV, several executives at the Ophthalmology Innovation Summit speak to EyewireTV about the main product candidates in their companies' pipeline. (2196 Views)

Watch Video

Wednesday, December 17, 2014

EyewireTV—AREDS Ocular Vitamins Study, Lucentis Designation for DR

In this week's EyewireTV, a study evaluating the top-selling ocular nutritional supplements finds that they contain the same ingredients as the AREDS and AREADS2 formulas, but not all contained the recommended doses; and the FDA grants breakthrough therapy designation for Lucentis (ranibizumab) for the treatment of diabetic retinopathy. Also, Shire provides updates on several products in its ophthalmic pipeline, including SHP607 for the prevention of retinopathy of prematurity, and lifitegrast for the treatment of dry eye disease. (2287 Views)

Watch Video

Wednesday, December 10, 2014

EyewireTV — Rhopressa Phase 3 Trial, Dropless Cataract Surgery

In this week’s EyewireTV, Aerie Pharmaceuticals completes enrollment in the 400-patient phase 3 clinical trial of glaucoma drug candidate Rhopressa; and CenterVue announces FDA 510(k) clearance for its Eidon true-color confocal scanner. In the feature, three ophthalmologists share their thoughts on providing anti-inflammatory and anti-bacterial agents during cataract surgery. (2761 Views)

Watch Video
Load More